Latent Tuberculosis
Conditions
Interventions
Clinical trial with a total of 162 patients, the duration of the study period will be from 6 to 12 months depending on the amount of dose to be administered. Control group: 81 patients without access
Device
L01.224.900.685
Sponsors
Universidade Federal do Espirito Santo
Universidade Federal do Espirito Santo
Eligibility
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients who agree with the consent form; Patients of both sexes; Indication for treatment with isoniazid 300mg per day; With access to mobile smartphone with Android operating system; patients who know or not read; age between 18 and 50 years;
Exclusion criteria
Exclusion criteria: Patients on treatment for rifampicin or already on treatment for latent tuberculosis; patients with HIV; pregnant or intending to become pregnant; homeless patients; deprived of liberty; Patients referred for treatment over 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adherence to Latent Tuberculosis Infection Treatment in Patients Using the App | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: Adherence to Latent Tuberculosis Infection Treatment in Patients Using the Application Whether Greater in Male or Female;Expected Outcome 2: Socioeconomic Characteristics of Study Participating Patients;Expected Outcome 3: Major Side Effects Reported by Patients;Expected Outcome 4: Key Patient Health History;Expected Outcome 5: Major Health-Related Lifestyle;Expected Outcome 6: Major Continuous-Use Drugs;Expected Outcome 7: Key Symptoms Patients Have Before Starting Latent Tuberculosis Treatment | — |
Countries
Brazil
Contacts
Public ContactEthel Maciel
Universidade Federal do Espirito Santo
Outcome results
None listed